Oncogenex Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011

Oncogenex Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Oncogenex Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Oncogenex Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oncogenex Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Oncogenex Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Oncogenex Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Oncogenex Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Oncogenex Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Oncogenex Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Oncogenex Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Oncogenex Pharmaceuticals, Inc. and identify potential opportunities in those areas. SHOW LESS READ MORE >

List of Tables
List of Figures
Oncogenex Pharmaceuticals, Inc. Snapshot
Oncogenex Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Oncogenex Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Oncogenex Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Oncogenex Pharmaceuticals, Inc. – Pipeline Products Glance
Oncogenex Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Oncogenex Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Oncogenex Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Oncogenex Pharmaceuticals, Inc. – Drug Profiles
Custirsen Sodium + Prednisone + Docetaxel
Product Description
Mechanism of Action
R&D Progress
OGX-011
Product Description
Mechanism of Action
R&D Progress
OGX-011 + Mitoxantrone
Product Description
Mechanism of Action
R&D Progress
OGX-011 + Taxotere
Product Description
Mechanism of Action
R&D Progress
OGX-427
Product Description
Mechanism of Action
R&D Progress
Tocosol Paclitaxel
Product Description
Mechanism of Action
R&D Progress
OGX-011
Product Description
Mechanism of Action
R&D Progress
OGX-011 + Taxotere
Product Description
Mechanism of Action
R&D Progress
OGX-427
Product Description
Mechanism of Action
R&D Progress
OGX-427 + Docetaxel
Product Description
Mechanism of Action
R&D Progress
SN2310
Product Description
Mechanism of Action
R&D Progress
CSP-9222
Product Description
Mechanism of Action
R&D Progress
OGX-225
Product Description
Mechanism of Action
R&D Progress
Oncogenex Pharmaceuticals, Inc. – Pipeline Analysis
Oncogenex Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Oncogenex Pharmaceuticals, Inc. - Pipeline Products By Target
Oncogenex Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Oncogenex Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Oncogenex Pharmaceuticals, Inc. – Recent Pipeline Updates
Oncogenex Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Oncogenex Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2011
Oncogenex Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2011
Oncogenex Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
Oncogenex Pharmaceuticals, Inc. Detailed Deal Summary
Equity Offering
OncoGenex Pharmaceuticals Completes Public Offering Of $9.5 Million
OncoGenex Technologies Withdraws Registration Statement For IPO
Isis Pharmaceuticals Expands Its Agreement With OncoGenex Technologies
Licensing Agreements
Teva Pharmaceutical Enters Into Licensing Agreement With Oncogenex Pharmaceuticals
Schering Signs Licensing Agreement With Sonus Pharmaceuticals
OncoGenex Technologies Enters Into Licensing Agreement With The University of British Columbia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Oncogenex Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
Oncogenex Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
Oncogenex Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
Oncogenex Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2011
Oncogenex Pharmaceuticals, Inc. – Phase III, 2011
Oncogenex Pharmaceuticals, Inc. - Phase II, 2011
Oncogenex Pharmaceuticals, Inc. - Phase I, 2011
Oncogenex Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2011
Oncogenex Pharmaceuticals, Inc. - Pipeline By Target, 2011
Oncogenex Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2011
Oncogenex Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2011
Oncogenex Pharmaceuticals, Inc. – Recent Pipeline Updates, 2011
Oncogenex Pharmaceuticals, Inc., Other Locations
Oncogenex Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011
Oncogenex Pharmaceuticals, Inc., Deals Summary by Region, 2004 to YTD 2011
Oncogenex Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
Oncogenex Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
Oncogenex Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
Oncogenex Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
Oncogenex Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2011
Oncogenex Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2011
Oncogenex Pharmaceuticals, Inc. - Pipeline By Target, 2011
Oncogenex Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2011
Oncogenex Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2011